Daniel S.W. Tan

Research interests

Publications

• Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations

  Journal of Clinical Oncology · 2022 · https://doi.org/10.1200/jco.21.01626

• Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.08.002

• Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer

  Journal of Thoracic Oncology · 2021 · https://doi.org/10.1016/j.jtho.2021.06.017

• Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00247-3

• Genomic landscape of lung adenocarcinoma in East Asians

  Nature Genetics · 2020 · https://doi.org/10.1038/s41588-019-0569-6

• Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

  The Lancet Respiratory Medicine · 2020 · https://doi.org/10.1016/s2213-2600(20)30154-5

• Efficacy of Selpercatinib in RET -Altered Thyroid Cancers

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2005651

• Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2002787

• Methionine is a metabolic dependency of tumor-initiating cells

  Nature Medicine · 2019 · https://doi.org/10.1038/s41591-019-0423-5

• Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR -Mutated, MET Factor–Dysregulated Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2018.77.7326

• Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates

  Nature · 2018 · https://doi.org/10.1038/s41586-018-0130-2

• First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)30123-x

• Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(15)00614-2

• Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression

  Nature Communications · 2016 · https://doi.org/10.1038/ncomms11702

• Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1311107

• A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

  Nature Medicine · 2012 · https://doi.org/10.1038/nm.2713

Current projects

No projects listed.